Logout Login Cart iconShop
Contact Sales

Search

Filters

Content Type

Products

Clear Filters

Search Results for "500k fc points price Buyfc26coins.com is FC 26 coins official site..uOKm"

Looking for quality documents?
external link icon
Repligen to Present at the Stifel 2015 Healthcare Conference
WALTHAM, Mass., Nov. 11, 2015 (GLOBE NEWSWIRE) - Repligen Corporation (NASDAQ:RGEN) today announced its upcoming presentation at the Stifel 2015 Healthcare Conference, being held next week at the Lotte New York Palace. Tony J. Hunt, Repligen President and Chief Executive Officer, will present a Company overview on Wednesday, November 18, at 8:00 a.m. EST. A live audio webcast of this discussion will be accessible through the Investor Events section of Company’s website. A replay of the webcast will also be accessible for a period of time following the event. About Repligen Corporation Repligen Corporation (NASDAQ:RGEN) is a life sciences company focused on the development and commercialization of high-value consumable products used in the process of manufacturing biological drugs. Our bioprocessing products are sold to major life sciences and biopharmaceutical companies worldwide. We are the leading manufacturer of Protein A affinity ligands, a critical component of Protein A media
external link icon
Repligen Completes Expansion of U.S. Facility
WALTHAM, Mass., Feb. 10, 2015 (GLOBE NEWSWIRE) - Repligen Corporation (Nasdaq:RGEN) announced today that it has completed an 11,000 square foot expansion of its U.S. manufacturing facility. The expansion includes a dedicated space for the production and assembly of Repligen's Alternating Tangential Flow System ("the ATF System"), the most recent addition to the Company's upstream bioprocessing product portfolio. The ATF System is a market-leading product line used to significantly increase cell density and product yield during the fermentation step of the biologic drug manufacturing process. The expansion includes areas for ATF System assembly, quality control and inventory, as well as cleanroom suites for the production of single-use ATF Systems in an ISO 7 environment that meets the high standards of Repligen's biopharmaceutical customers. "This expansion satisfies our goal to rapidly transfer ATF System operations, which we acquired from Refine Technology of
external link icon
Repligen Receives Milestone Payment From Pfizer
WALTHAM, Mass., Jan. 8, 2015 (GLOBE NEWSWIRE) - Repligen Corporation (Nasdaq:RGEN) announced today that on December 30, 2014, it received a $1 million milestone payment from Pfizer, Inc. under the terms of the companies' exclusive worldwide licensing agreement (the "Agreement") for the development of compounds to potentially treat spinal muscular atrophy (SMA), a neuromuscular disease that typically presents in children under age two. Since announcing the Agreement in January 2013, Repligen has received $7 million in upfront and milestone payments. Repligen remains eligible to receive up to $63 million in additional performance-based milestone payments, as well as royalties on any future sales of compounds developed under the Agreement. 2014 Revenue Repligen also today reported preliminary, unaudited total revenue of $63-$63.5 million for the fiscal year ended December 31, 2014. This total revenue figure is comprised of approximately $3 million in revenue from out-licensed therapeutic
external link icon
Repligen to Present at Stifel Healthcare Conference 2014
WALTHAM, Mass., Nov. 12, 2014 (GLOBE NEWSWIRE) - Repligen Corporation (Nasdaq:RGEN) today announced that Walter C. Herlihy, Ph.D., President and Chief Executive Officer, will present at the Stifel Healthcare Conference 2014 on Wednesday, November 19 at 10:55 a.m. EST. The conference will be held at the New York Palace Hotel in New York City. The Repligen presentation will be webcast live and will be accessible through the Investor Events section of Company's website. The webcast and slide presentation will also be archived on the Company's website for a period of time following the event. About Repligen Corporation Repligen Corporation (Nasdaq:RGEN) is a life sciences company focused on the development and commercialization of high-value consumable products used in the process of manufacturing biological drugs. Our bioprocessing products are sold to major life sciences and biopharmaceutical companies worldwide. We are the leading manufacturer of Protein A affinity ligands, a critical
external link icon
Repligen to Host Investor & Analyst Event on October 16
- Discussion of Biomanufacturing Trends and Technologies Will be Webcast - WALTHAM, Mass., Oct. 10, 2014 (GLOBE NEWSWIRE) -Repligen Corporation (Nasdaq:RGEN) today announced that the Company will host an Investor & Analyst Event on October 16, 2014 in New York. The event, which will begin at 8:00 a.m. and conclude by 9:30 a.m. (EDT), will feature a presentation by Howard L. Levine, Ph.D., co-founder and President of BioProcess Technology Consultants. Dr. Levine is a recognized thought leader and published expert on the subject of biopharmeceuticals process development and manufacturing. Repligen speakers will include key members of the Company's management team: Walter C. Herlihy, Ph.D., President and CEO; Tony J. Hunt, COO; and Jon K. Snodgres, CFO. Dr. Levine will discuss factors that are driving significant changes in biomanufacturing, and Repligen management will discuss the Company's role in advancing bioprocessing technologies that increase facility efficiency and
external link icon
Repligen to Present at Jefferies 2014 Global Healthcare Conference
WALTHAM, Mass., May 28, 2014 (GLOBE NEWSWIRE) - Repligen Corporation (Nasdaq:RGEN) today announced that Walter C. Herlihy, Ph.D., President and Chief Executive Officer, will present an overview of the Company at the Jefferies 2014 Global Healthcare Conference at 8:00 a.m. EDT on Wednesday, June 4. The conference will be held June 2-5, 2014 at The Grand Hyatt New York. A live audio webcast of the Repligen presentation will be accessible through the Investor Relations section of Company website at www.repligen.com ; see News & Events, Events & Presentations. A replay of the webcast will also available for a period of time following the conference. About Repligen Corporation Repligen Corporation (Nasdaq:RGEN) is a life sciences company focused on the development, production and commercialization of high-value consumable products used in the process of manufacturing biologic drugs. Our bioprocessing products are sold to major life sciences and biopharmaceutical companies
external link icon
Repligen Hires Former Life Technologies Executive Tony J. Hunt as Chief Operating Officer
WALTHAM, Mass., May 6, 2014 (GLOBE NEWSWIRE) - Repligen Corporation, a life sciences company focused on the manufacture and commercialization of bioprocessing products, today announced the appointment of Tony J. Hunt to the newly created position of Chief Operating Officer. Mr. Hunt was most recently President, BioProduction at Life Technologies, a global life sciences company whose acquisition by Thermo Fisher Scientific was completed earlier this year. At Life Technologies, Mr. Hunt played a key role in the development and growth of the company's bioprocessing business, where he focused on expanding the upstream Gibco® cell culture franchise and building the downstream purification and analytics franchises. Mr. Hunt is an accomplished life sciences industry veteran who will oversee commercial and manufacturing operations for Repligen. "We welcome Tony to the Repligen management team, where his industry knowledge and understanding of bioproduction market drivers will help guide the
external link icon
Repligen to Present at the 2013 Stephens Fall Investment Conference
WALTHAM, Mass., Nov. 6, 2013 (GLOBE NEWSWIRE) - Repligen Corporation (Nasdaq:RGEN) today announced that Walter C. Herlihy, Ph.D., President and Chief Executive Officer, will present an overview of the Company at the Stephens Fall Investment Conference on Wednesday, November 13 at 10:00 a.m. EST. The annual conference will take place November 12-13, 2013 at the New York Palace Hotel in New York. The Repligen presentation will not be webcast, however the slide presentation will be available on the Company's website at www.repligen.com ; see Events & Presentations under Investor Relations. About Repligen Corporation Repligen Corporation is a life sciences company focused on the development, production and commercialization of high-value consumable products used in the process of manufacturing biological drugs. Our bioprocessing products are sold to major life sciences and biopharmaceutical companies worldwide. We are a leading manufacturer of Protein A, a critical reagent used to
external link icon
Repligen to Present at the Stifel Healthcare Conference 2013
WALTHAM, Mass., Sept. 4, 2013 (GLOBE NEWSWIRE) - Repligen Corporation (Nasdaq:RGEN) today announced that Walter C. Herlihy, Ph.D., President and Chief Executive Officer, will present an overview of the Company at the Stifel Healthcare Conference on Wednesday, September 11, 2013 at 3:50 p.m. EDT. The annual conference will take place September 11-12 at the Four Seasons Hotel in Boston. The Repligen presentation will be webcast live and can be accessed through the Investors section of Company's website at www.repligen.com . The webcast and slide presentation will also be archived for a period of time on the Company's website. About Repligen Corporation Repligen Corporation (Nasdaq:RGEN) is a life sciences company focused on the development, production and commercialization of high-value consumable products used in the process of manufacturing biological drugs. Our bioprocessing products are sold to major life sciences and biopharmaceutical companies worldwide. We are a leading
external link icon
Repligen CEO to Present at Jefferies 2013 Global Healthcare Conference
WALTHAM, Mass., May 23, 2013 (GLOBE NEWSWIRE) - Repligen Corporation (Nasdaq:RGEN) today announced that Walter C. Herlihy, Ph.D., President and Chief Executive Officer, will present a corporate update at the Jefferies 2013 Global Healthcare Conference on Monday, June 3, 2013, at 4:30 p.m. EDT. The conference will take place June 3-6 at the Grand Hyatt New York. The Repligen presentation will be webcast live and can be accessed through the Investors section of Company's website at www.repligen.com . The webcast and slide presentation will also be archived for a period of time on the Company's website. About Repligen Corporation Repligen Corporation (Nasdaq:RGEN) is a life sciences company focused on the development, production and commercialization of high-value consumable products used in the process of manufacturing biological drugs. Our bioprocessing products are sold to major life sciences and biopharmaceutical companies worldwide. We are a leading manufacturer of Protein A, a
Close modal

A new look. A better way to explore Repligen.

We’ve redesigned Repligen.com to help you find the right solutions faster, with greater clarity and less effort.

Find what you need faster
Get to the right information with quicker site speed

Explore the site with ease
Navigate easily with an intuitive, simple site structure

Access product details instantly
Find products and resources faster, in fewer clicks

Get support when you need it
Connect with our team when you need support